Sanofi India Limited

Sanofi India Limited

Sanofi India Limited has received a Show Cause Notice from the Additional Commissioner of CGST and CX, Mumbai East, alleging misclassification of certain products at a concessional rate of 5% instead of 12% for the financial year 2020-21, resulting in a proposed tax liability of Rs. 36,38,70,979 and a proposed penalty of Rs. 36,38,70,979. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.

Sanofi India Limited

Sanofi India Limited has submitted a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding an order passed by the Deputy Commissioner, Central Goods & Service Tax, Division –IV, Margao–Goa, which has accepted and sanctioned a GST refund of Rs.1,32,93,535.

Sanofi India Limited

Sanofi India Limited has disclosed an order passed by the Assistant Commissioner of Income Tax, TDS OSD TDS Circle 2(2), Mumbai, giving effect to a favourable action taken by the Commissioner of Income Tax Appeal (CIT(A)) - 49, Mumbai, for AY 2019-20, dropping the proceedings initiated under Section 201 of the Income-tax Act, 1961, thereby deleting the demand of Rs. 72,71,511.

Sanofi India Limited

Sanofi India Limited has announced its unaudited financial results for the quarter and half year ended 30th June 2026, with a strong momentum in the diabetes business, driven by double-digit growth in the domestic market, powered by innovative portfolio, Toujeo and Soliqua. The company has also reported a 2% growth in quarter two over last year's quarter two, based on the continued ROI from partnership with Emcure and Cipla.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the link of video recording of investor/analysts call for update on unaudited financial results for the quarter and half year ended 30th June 2026.

Sanofi India Limited

Sanofi India Limited has published its unaudited financial results for the quarter and half year ended 30th June 2026, showing a net profit of ₹57.60 crore and a total comprehensive income of ₹44.74 crore.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about Investor / Analysts Call - Presentation for Q2/26 results, highlighting strong momentum in diabetes business with 8% growth, driven by innovative portfolio and partnerships.

Sanofi India Limited

Sanofi India Limited has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong sales of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about Re-constitution of the Committees of the Company. The Board of Directors at its meeting held today, considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2026. The company reported domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The Insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter.

Sanofi India Limited

Sanofi India Limited has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14%, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.

Sanofi India Limited

Sanofi India Limited has announced its financial results for the quarter ended June 30, 2026, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, and profits before tax and exceptional items increased 19% to INR 112 crores.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the change in Senior Management Personnel, specifically the cessation of Mr. Nakul Verma as Public Affairs & Market Access-Head, effective July 31st, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the schedule of an investor/analysts call for an update on unaudited financial results for the quarter and half year ended 30th June 2026.

Sanofi India Limited

Sanofi India Limited has announced the resignation of Mr. Rachid Ayari as Whole Time Director and Chief Financial Officer, effective September 30, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has announced the resignation of Mr. Rachid Ayari as Chief Financial Officer, effective September 30, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about the change in management, with Mr. Rachid Ayari stepping down as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel on September 30, 2026, to transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has informed the Exchange regarding Change in Director(s) of the company. Mr. Rachid Ayari will step down as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel on 30th September 2026 to transition to another role within the Sanofi group.

Sanofi India Limited

Sanofi India Limited has received a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026, confirming the dematerialization of securities and listing on stock exchanges.

Sanofi India Limited

Sanofi India Limited has informed the Exchange about disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a favourable order issued by the Income Tax Department- Office of the Commissioner of Income tax Appeal - 49, Mumbai, dropping the proceedings initiated under Section 201 of the Income-tax Act, 1961, for Assessment Year 2019-20.